^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    IPH5301

    i
    Other names: IPH5301, IPH53, IPH 5301, IPH 53, anti-huCD73 mAb
    Associations

    News

    Trials
    Company:
    Innate
    Drug class:
    CD73 inhibitor
    Related drugs:
    Associations

    News

    Trials
    10d
    Design, engineering, and functional evaluation of nanobody-based anti-CD73 for immunogenic cell death induction in chemoresistant colorectal Cancer cell line. (PubMed, Int Immunopharmacol)
    HeLiNa-73 combines CD73 inhibition with ICD induction, thereby overcoming adenosine-mediated immune suppression while enhancing tumor immunogenicity. These in vitro findings highlight HeLiNa-73 as a next-generation nanobody-based candidate for in vivo chemoresistant CRC studies and to synergize with checkpoint blockade.
    Preclinical • Journal
    |
    HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin) • CD80 (CD80 Molecule) • CD86 (CD86 Molecule)
    |
    IPH5301
    almost2years
    CHANCES: A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=27, Recruiting, Institut Paoli-Calmettes | Trial completion date: Feb 2025 --> Feb 2026 | Trial primary completion date: Mar 2024 --> Mar 2025
    Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 positive • HER-2 overexpression
    |
    Herceptin (trastuzumab) • paclitaxel • IPH5301